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Contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS) with contrast agent enabled us to 
assess the hemodynamics closely,  despite limited data in pancreatic tumors.  We have initiated a pro-
spective,  single arm,  and non-randomized study to clarify the accuracy and safety of CH-EUS with 
Sonazoid and time-intensity curve (TIC) analysis for diagnosing benign or malignant pancreatic 
tumors.  A total of 200 patients will undergo CH-EUS and TIC analysis.  Receiver operating character-
istic (ROC) analysis will be used to determine the optimal parameter cutoﬀ values for TIC analysis.  
This will clarify whether CH-EUS and TIC can further improve the diagnosis of pancreatic tumors 
over conventional EUS.
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I t is widely accepted that endoscopic ultrasonog-raphy (EUS) is useful for the diagnosis of pan-
creatic diseases [1,  2] because EUS is superior to 
any other current modality with respect to spatial 
resolution [3].  Therefore,  EUS is one of the most 
reliable modalities for the detection of detailed fea-
tures in pancreatic tumors.  However,  even with EUS,  
the diﬀerential diagnosis of pancreatic tumors remains 
a problem.  EUS also has limitations in evaluating 
dynamic perfusion imaging of pancreatic tumors.  
Doppler mode EUS with contrast agents cannot ade-
quately detect signals from microbubbles in very slow 
ﬂowing microscopic vessels and in parenchymal perfu-
sion [4],  and the results are often accompanied by 
artifacts such as blooming.
　 Recently,  due to advances in ultrasonographic 
technology and the clinical application of second-gen-
eration intravenous contrast agents such as Sonazoid 
(Daiichi-Sankyo,  Tokyo,  Japan),  contrast-enhanced 
harmonic EUS (CH-EUS) has enabled us to be able to 
assess the microvasculature without Doppler-related 
artifacts and to evaluate the hemodynamics of the 
target lesion in real-time.  Close observation of the 
hemodynamics may be useful in the diagnosis of pan-
creatic tumors.  Moreover,  echo intensity changes can 
be measured and a time-intensity curve (TIC) can be 
obtained,  we can quantitatively analyze the blood ﬂow 
in the tumor microvasculature.
　 Unfortunately,  there are limited data on the dif-
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ferential diagnosis of solid and cystic pancreatic 
tumors using CH-EUS and there are few reports on 
the diﬀerential diagnosis of a pancreatic tumor using 
CH-EUS with TIC analysis [5].  The aim of this study 
is to analyze the accuracy of CH-EUS with intrave-
nous Sonazoid and TIC analysis for diagnosing benign 
or malignant pancreatic tumors by exploring the opti-
mal cutoﬀ values for several relevant parameters,  
such as the vascularity pattern of pancreatic tumors in 
comparison with the surrounding pancreatic paren-
chyma.  Our ﬁnding could provide information as to 
whether CH-EUS and TIC analysis can aid the dif-
ferential diagnosis of pancreatic tumors detected by 
conventional EUS.
Endpoints
　 Study Design and endpoints. A single-arm,  
prospective,  non-randomized,  open label trial will be 
conducted to evaluate the usefulness and safety of 
CH-EUS and TIC analysis in the diﬀerential diagnosis 
of pancreatic tumors.  The primary outcome parameter 
is the diagnostic ability of CH-EUS and whether 
CH-EUS can aid in the diﬀerential diagnosis of pan-
creatic tumors detected by conventional EUS.  
Secondary outcome parameters include the diagnostic 
ability of CH-EUS compared to conventional B-mode 
EUS and multidetector-row computed tomography 
(MDCT),  and the dignostic ability of CH-EUS with 
time-intensity curve analysis in diﬀerentiating pancre-
atic tumors,  and the safety of CH-EUS with Sonazoid.
Eligibility Criteria
　 All patients who meet the main inclusion and exclu-
sion criteria will be invited.  The inclusion and exclu-
sion criteria are listed in Table 1.
　 The study is approved by our institutional review 
board (No. 1845),  and we will obtain informed consent 
from all patients.
Treatment Methods
　 EUS and CH-EUS imaging. Before undergo-
ing CH-EUS,  all patients will undergo fundamental 
B-mode EUS for pancreatic tumor evaluation.  EUS 
examinations and ultrasonography imaging analyses 
will be performed with a GF-UE260-AL5 device 
(Olympus,  Tokyo,  Japan) and an ALOKA ProSound 
SSD α-10 device (Aloka,  Tokyo,  Japan),  respectively.  
The bolus of Sonazoid contrast agent (Daiichi Sankyo,  
Tokyo,  Japan) will then be administered intravenously 
in order to evaluate the blood ﬂow of the tumor micro-
vasculature.  The tumor will then be observed continu-
ously for 120 sec in order to compare its enhancement 
with that of the surrounding pancreatic parenchyma.
　 Safety is evaluated by the onsite investigators.  
Blood pressure,  heart rate and saturation pulse oxim-
etry are measured before,  during,  and immediately 
after the examination.  If they are abnormal,  clinical 
chemical parameters are assessed within 24 h.  Thus,  
patients are observed for adverse events.
　 Time-intensity curve analysis. The digital 
CH-EUS data that is generated will be stored on the 
hard drive of the ultrasonography imaging system.  
Two circular regions of interest (ROI) will be placed 
on the pancreatic tumor and the normal pancreatic 
parenchyma.  The echo intensity in the ROI will be 
quantiﬁed,  and the time-intensity curve will be calcu-
lated using the software program built into the ultra-
sonography imaging system.
　 We will quantitatively analyze the blood ﬂow in the 
tumor microvasculature from several aspects using 
time‒intensity curve analysis.  The following parame-
ters will be measured (Fig.  1): (i) echo intensity change 
from baseline to peak,  (ii) time to contrast enhance-
ment peak,  (iii) velocity of contrast imaging from 
baseline to peak,  (iv) echo intensity reduction rate 
from peak to 120 sec after injection,  and (v) nodule/
pancreatic parenchyma contrast ratio.  These param-
eters will be compared between pancreatic tumor types 
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Table 1　 Patient eligibility
Inclusion criteria
Patients with pancreatic tumors detected by fundamental EUS
Aged 20 years or older
Witten informed consent
Exclusion criteria
Allergy to eggs and Sonazoid
Karnofsky performance status (KPS) less than 50%
Risk of bleeding as deﬁned below: platelets less than 50,000/µL, 
Prothrombin time less than 50%
Severe complication in other organs, such as heart failure, 
hepatic failure and so on
Without written informed consent
Physician judged improper to entry this trial
to identify any signiﬁcant diﬀerences.
　 Outcome measures. The primary outcome is 
the determination of diagnostic accuracy of TIC analy-
sis for malignant or benign tumor.  The Youden-index,  
a summary measure from receiver operating charac-
teristic (ROC) analysis,  will be utilized to determine 
the optimal cutoﬀ values of the echo intensity change,  
echo intensity reduction rate,  and nodule/pancreatic 
parenchyma contrast ratio in order to obtain the best 
combination of sensitivity/speciﬁcity values and to 
classify patients into those with benign and those with 
malignant tumors.  Final diagnoses will be based on the 
histology of the resected specimens or the histology 
and cytology of samples obtained by EUS-ﬁne needle 
aspiration (EUS-FNA).
Statistical Consideration
　 Statistical analysis will be performed using the 
JMP software program version 8.0 (SAS Institute,  
Cary,  NC,  USA).  Continuous values will be presented 
as the median and interquartile range and the two 
populations will be compared using the Mann-Whitney 
U test.  P values＜0.05 will be considered to be statis-
tically signiﬁcant.
　The diagnostic accuracy of conventional EUS was 
76  from the retrospective study in our institution.  
We estimated that 20  elevation of diagnostic accu-
racy is expected by using CH-EUS with Sonazoid.  
The historical control data are based on the histology 
of the resected specimens or the histology and cytol-
ogy of samples obtained by EUS-FNA.  We consider 
the lower limit of interest to be 10 .  We donʼt have 
relevant data regarding the additional expected eﬀect 
of CH-EUS,  so instead simply assumed that a 20  or 
more increase in diagnostic ability of pancreatic 
tumors would be clinically meaningful.  The sample 
size of this study was estimated to be 120 patients,  
with a 1-sided α=0.05 and 1-β=0.8.  However,  it is 
sometimes diﬃcult hold target images continuously 
with EUS during this procedure due to respiratory 
movement and patientʼs body motion,  which makes it 
diﬃcult to measure TIC.  We experience such case in 
one-in-three patient.  Therefore,  we aim for accumu-
lating 200 patients.
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Fig. 1　 A representative schematic of a time-intensity character-
istic peak showing how the parameters will be measured.  Ipeak－
Ibase: echo intensity change from baseline to peak; tpeak: time to 
contrast enhancement peak; (Ipeak－Ibase)/tpeak: velocity of contrast 
imaging from baseline to peak; (Ipeak－I120)/Ipeak: echo intensity 
reduction rate; (Ipeak－Ibase,  of nodule)/(Ipeak－Ibase,  of parenchyma) :  
nodule/pancreatic parenchyma contrast ratio.
